Welcome to our dedicated page for Jade Biosciences news (Ticker: JBIO), a resource for investors and traders seeking the latest updates and insights on Jade Biosciences stock.
Jade Biosciences develops monoclonal antibody therapies for autoimmune diseases, with company updates centered on clinical execution, pipeline expansion, and financing. Its lead program, JADE101, targets APRIL and is being developed for immunoglobulin A nephropathy; additional programs include JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, and JADE301, an antibody program in preclinical development.
Recurring news includes financial results, corporate updates, clinical and biomarker data presentations, research conference participation, private placement financing, equity inducement grants, and leadership changes tied to the company's research and development organization.
Jade Biosciences (NASDAQ:JBIO) has initiated dosing in its Phase 1 clinical trial of JADE101, a novel anti-APRIL monoclonal antibody targeting IgA nephropathy (IgAN). The trial marks a significant milestone in developing a potential best-in-class treatment for this autoimmune kidney disease.
The Phase 1 study is designed as a randomized, double-blind, placebo-controlled trial evaluating single ascending subcutaneous doses in healthy volunteers. The company expects to report interim data in H1 2026, which will help determine optimal dosing strategies for future IgAN patient studies.
JADE101 has demonstrated promising preclinical results, including femtomolar binding affinity to APRIL and sustained IgA reductions in non-human primates, suggesting potential for convenient eight-week or longer dosing intervals.
Jade Biosciences (Nasdaq: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in three upcoming healthcare conferences in September 2025.
The company will participate in the Cantor Global Healthcare Conference (September 3-5), the Stifel Virtual Immunology and Inflammation Forum (September 15-16), and the 11th Annual World Medical Innovation Forum (September 15-17). Management will conduct fireside chats and participate in a panel discussion on immunology, while also hosting one-on-one investor meetings.
Webcasts of the Cantor and Stifel fireside chats will be available on Jade's website with 90-day replay access.
Jade Biosciences (NASDAQ:JBIO) reported Q2 2025 financial results and corporate updates, highlighting progress in its autoimmune disease therapy development. The company's lead candidate JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrated promising preclinical results with ultra-high binding affinity and sustained IgA suppression. A Phase 1 trial is expected to begin in Q3 2025.
Financial highlights include $220.9 million in cash and equivalents, providing runway through 2027. Q2 2025 saw R&D expenses of $22.5 million and G&A expenses of $5.2 million, with a net loss of $32.1 million. The company also appointed Brad Dahms as CFO and continues development of JADE201, targeting multiple systemic autoimmune diseases, with clinical entry planned for H1 2026.
Jade Biosciences (Nasdaq: JBIO), a biotechnology company developing therapies for autoimmune diseases, has announced its participation in two upcoming investor conferences.
CEO Tom Frohlich and CSO Dr. Andrew King will present at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 3:00 p.m. ET, and the 2025 Stifel Biotech Summer Summit on August 13, 2025, at 7:30 a.m. ET. The management team will also host one-on-one investor meetings during both events.
Jade Biosciences (NASDAQ:JBIO), a biotechnology company developing therapies for autoimmune diseases, has appointed Brad Dahms as Chief Financial Officer. Dahms brings significant experience from his previous roles as CFO and CBO at IDRx, where he orchestrated its sale to GSK for up to $1.15 billion, and as CFO of Theseus Pharmaceuticals and Selecta Biosciences.
The appointment comes as Jade prepares to advance its lead candidate JADE101 into clinical trials for IgA nephropathy this year. The company aims to leverage Dahms' expertise in financial operations, business development, and capital markets following its recent Nasdaq listing and private financing round.
The company's lead candidate JADE101, an anti-APRIL monoclonal antibody for IgAN, is expected to begin first-in-human trials in H2 2025, with interim data expected in H1 2026. Additionally, Jade nominated JADE201 as a development candidate from their JADE-002 program.
Financial results show cash and equivalents of $49.9 million as of March 31, 2025, with an additional $205 million gross proceeds from the April merger. Q1 2025 saw R&D expenses of $20.0 million, G&A expenses of $3.4 million, and a net loss of $38.2 million. The company expects its current cash position to provide runway through 2027.
Jade Biosciences (NASDAQ: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference from June 3-5, 2025, in New York. CEO Tom Frohlich will deliver a company presentation on June 4 at 4:55-5:25 p.m. ET. The management team will also conduct investor meetings during the event.
The presentation will be accessible to investors and the public through the Investors and Media section of JadeBiosciences.com, with the recording remaining available for 90 days afterward.